Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cellumed Co., Ltd. (049180:KRX), powered by AI.
Cellumed Co., Ltd. is currently trading at ₩1,009. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cellumed Co., Ltd. on Alpha Lenz.
Cellumed Co., Ltd.'s P/E ratio is -1.6.
“Cellumed Co., Ltd. trades at a P/E of -1.6 (undervalued) with modest ROE of -202.0%.”
Ask for details →Cellumed Co., Ltd. is a biomedical company that specializes in the development and production of advanced medical products. The company focuses primarily on regenerative medicine and cell therapy technologies, seeking to provide innovative solutions for various medical conditions. Cellumed Co., Ltd. plays a key role in the healthcare and biotechnology sectors, offering products that support the treatment of serious and chronic diseases. The company's commitment to research and development positions it as a significant participant in the growing global market for biopharmaceuticals and advanced therapeutics. By leveraging cutting-edge technologies, Cellumed Co., Ltd. contributes to the advancement of medical care and improved patient outcomes. This specialized approach not only enhances its market presence but also underscores its importance in the field of innovative healthcare solutions.
“Cellumed Co., Ltd. trades at a P/E of -1.6 (undervalued) with modest ROE of -202.0%.”
Ask for details →Cellumed Co., Ltd. (ticker: 049180) is a company listed on KRX in the Healthcare sector (Medical Instruments & Supplies). It has approximately 93 employees. Market cap is $55.5B.
The current price is ₩1,009 with a P/E ratio of -1.56x and P/B of 5.59x.
ROE is -201.97% and operating margin is -17.52%. Annual revenue is $129.1B.